Cargando…
No Evidence of Harms of Probiotic Lactobacillus rhamnosus GG ATCC 53103 in Healthy Elderly—A Phase I Open Label Study to Assess Safety, Tolerability and Cytokine Responses
BACKGROUND: Although Lactobacillus rhamnosus GG ATCC 53103 (LGG) has been consumed by 2 to 5 million people daily since the mid 1990s, there are few clinical trials describing potential harms of LGG, particularly in the elderly. OBJECTIVES: The primary objective of this open label clinical trial is...
Autores principales: | Hibberd, Patricia L., Kleimola, Lauren, Fiorino, Anne-Maria, Botelho, Christine, Haverkamp, Miriam, Andreyeva, Irina, Poutsiaka, Debra, Fraser, Claire, Solano-Aguilar, Gloria, Snydman, David R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4249962/ https://www.ncbi.nlm.nih.gov/pubmed/25438151 http://dx.doi.org/10.1371/journal.pone.0113456 |
Ejemplares similares
-
Transcriptomic Profile of Whole Blood Cells from Elderly Subjects Fed Probiotic Bacteria Lactobacillus rhamnosus GG ATCC 53103 (LGG) in a Phase I Open Label Study
por: Solano-Aguilar, Gloria, et al.
Publicado: (2016) -
Lactobacillus rhamnosus GG (ATCC 53103) for the Management of Infantile Colic: A Randomized Controlled Trial
por: Savino, Francesco, et al.
Publicado: (2020) -
Lactobacillus rhamnosus GG ATCC53103 and Lactobacillus plantarum JL01 improved nitrogen metabolism in weaned piglets by regulating the intestinal flora structure and portal vein metabolites
por: He, Feng, et al.
Publicado: (2023) -
Lactobacillus rhamnosus GG as an Effective Probiotic for Murine Giardiasis
por: Goyal, Nisha, et al.
Publicado: (2011) -
Anti-Biofilm Properties of Saccharomyces cerevisiae CNCM I-3856 and Lacticaseibacillus rhamnosus ATCC 53103 Probiotics against G. vaginalis
por: Sabbatini, Samuele, et al.
Publicado: (2020)